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Background: Although ginsenosides such as Rg1, Rb1 and Rg3 have shown promise as potential nutra-
ceuticals for cognitive impairment, their use has been limited due to high production cost and low
potency. In particular, the process of extracting pure Rg3 from ginseng is laborious and expensive.
Methods: We described the methods in preparing ginseol k-g3, an Rg3-enriched fraction, and evaluated
its effects on scopolamine-induced memory impairment in mice.
Results: Ginseol k-g3 (25e200 mg/kg) signiﬁcantly reversed scopolamine-induced cognitive impairment
in the passive avoidance, but not in Y-maze testing. Ginseol k-g3 (50 and 200 mg/kg) improved escape
latency in training trials and increased swimming times within the target zone of the Morris water maze.
The effect of ginseol k-g3 on the water maze task was more potent than that of Rg3 or Red ginseng. Acute
or subchronic (6 d) treatment of ginseol k-g3 did not alter normal locomotor activity of mice in an open
ﬁeld. Ginseol k-g3 did not inhibit acetylcholinesterase activity, unlike donezepil, an acetylcholinesterase
inhibitor. Rg3 enrichment through the ginseol k-g3 fraction enhanced the efﬁcacy of Rg3 in scopolamine-
induced memory impairment in mice as demonstrated in the Morris water maze task.
Conclusion: The effects of ginseol k-g3 in ameliorating scopolamine-induced memory impairment in the
passive avoidance and Morris water maze tests indicate its speciﬁc inﬂuence on reference or long-term
memory. The mechanism underlying the reversal of scopolamine-induced amnesia by ginseol k-g3 is not
yet known, but is not related to anticholinesterase-like activity.
opyright  2013, The Korean Society of Ginseng, Published by Elsevier. Open access under CC BY-NC-ND license. 1. Introduction
Alzheimer’s disease (AD), the most common age-related
neurodegenerative disorder [1], is characterized by the formation
of neuroﬁbrillary tangles in the medial temporal lobe and cortical
areas of the brain [2] and senile plaques [3]. The brains of patients
with AD show losses of choline acetyltransferase activity or basal
forebrain cholinergic neurons, which are correlated with cognitive
impairments [4e6]. The current mainstay of treatment for cogni-
tive loss associated with AD has been muscarinic or nicotinic re-
ceptor ligands and acetylcholinesterase (AChE) inhibitors [7], drugsfor Neuroscience, Sahmyook Univ
inseng, Published by Elsevier. Opewhich also show unwanted side effects such as diarrhea, nausea,
vomiting, muscle cramps, sedation and bradycardia [8].
Ginseng (the root of Panax ginseng Meyer) is frequently used in
Asian countries as a traditional medicine. The major components of
ginseng are ginsenosides; a diverse group of steroidal saponins
[9,10] capable of exerting many beneﬁcial effects including
enhancement of memory and cognitive functions. Acceleration of
memory acquisition and improved cognition has been reported
with treatment of ginsenosides Rb1 and Rg1 in animal models
[11,12]. For instance, Rg1 exerted ameliorative effects on scopol-
amine-induced memory impairment in rats in a radial arm mazeersity, 26-21 Kongreung-2-dong, Hwarangro-815, Nowon-gu, Seoul 139-742, Korea.
n access under CC BY-NC-ND license. 
J Ginseng Res 2014;38:1e72task [13], while Rb1 improved Abeta (25e35) induced memory
dysfunction, axonal hypertrophy, and synaptic loss in a mouse
model of AD [14]. Both ginsenosides enhanced cholinergic function
[15], conferred neuroprotection [16], and promoted neurite
outgrowth in cultured neurons [17]. Thesemechanisms are thought
to explain the memory-enhancing activities of these ginsenosides.
Rg3, another type of ginsenoside, has also been shown to
protect against scopolamine-induced memory deﬁcit in mice [18e
20]. Scopolamine is an antimuscarinic agent that decreases central
cholinergic activity and causes impairment of learning and
memory [21]. Moreover, the neuroprotective effects of Rg3 have
also been demonstrated in many studies [15,22e25]. In fact, Rg3
was the most effective ginsenoside in inhibiting N-methyl-D-
aspartic-acid-induced neurotoxicity in hippocampal neurons [26].
Rg3 was also observed to produce the most signiﬁcant reduction
of accumulation of the Alzheimer’s amyloid b peptide in a cell-
based model system, as well as in a mouse model of AD [27].
Altogether, these studies indicate the potentiality of Rg3 in the
treatment of AD.
Despite the attractive features of ginsenosides as potential
nutraceuticals for AD, their use has been limited for several reasons,
including high production cost and poor bioavailability. In partic-
ular, the process of extracting pure Rg3 from ginseng is laborious
and expensive [28]. Furthermore, conventional manufacturing
processes produce only minimal amounts of Rg3. Thus, Rg3
enrichment methods are required to ensure higher yields, which in
turn could increase bioavailability and efﬁcacy of the ginsenoside.
Moreover, although enriched with Rg3, these fractions may also
contain other beneﬁcial ginsenosides or phytochemicals that may
exert other important biological activities. For these reasons, Rg3-
enriched preparations may be more attractive formulations than
preparations containing puriﬁed Rg3 alone, from a drug develop-
ment standpoint.
In this study, we investigated the production of ginseol k-g3; an
Rg3-enriched fraction. Furthermore, we evaluated the efﬁcacy of
this preparation in ameliorating scopolamine-induced memory
impairment in mice. In addition, we examined whether the effects
of ginseol k-g3 were mediated via cholinergic signaling by
measuring in vitro its capacity to inhibit AChE activity.
2. Materials and methods
2.1. Animals
Male ICR mice (20e25 g), obtained from Hanlim Laboratory
Animals Co. (Hwasung, Korea), were used in this study. They were
maintained on a standard lightedark cycle, at ambient temperature
(22 2C) and humidity (55 5%), with free access to chow pellets
and water. Prior to behavioral assays, mice were acclimated to their
home cages for at least 6 d. The experimental groups, consisting of
eight to 10 animals per drug and dose, were chosen by means of a
randomized schedule. All mice were used only once. Animal
treatment and maintenance were carried out in accordance with
the Principles of Laboratory Animal Care (NIH publication No. 85-
23 revised 1985) and the Animal Care and Use Guidelines of Sah-
myook University, Korea.
2.2. Materials
The water extract of red ginseng (RG) was obtained from the
Korea Ginseng Corporation (Seoul, Korea). RG was given orally
(p.o.) at a dose of 100 mg/kg. Meanwhile, Rg3, obtained from
VitroSys Inc. (Yeongju, Korea), was prepared in 10% Tween 80 so-
lution and given at doses of 20 and 40 mg/kg (p.o.). Ginseol k-g3,
prepared using the methods stated below, was obtained fromCheiljedang Corp. (Seoul, Korea), dissolved in saline, and given to
mice (p.o.) at doses of 12.5 mg/kg, 25 mg/kg, 50 mg/kg, 100 mg/kg
and 200 mg/kg. Selection of doses was based on results from our
preliminary studies (unpublished ﬁndings). The control group was
given saline solution. Donepezil, an AChE inhibitor used as positive
control, was purchased from Sigma (St. Louis, MO, USA). The drug
was given at a dose of 5 mg/kg (p.o.). Scopolamine hydrochloride
was obtained from Sigma.
2.3. Preparation of ginsenoside Rg3-enriched fraction from Ginseng
Dried Korean ginseng (Panax ginseng) root was purchased from
Ginseng Nonghyup (Punggi, Korea). Korean ginseng was extracted
three times with 10 volumes of 70% fermentation ethanol at 80C
for 4 h, and then concentrated twice under vacuum at 50C. The
crude extract was suspended in distilled water and then subjected
to DIAION HP20 column chromatography (Mitsubishi Chemical
Industries, Tokyo, Japan), with successive elution by distilled water
and 50e100% v/v fermentation ethanol at room temperature. The
eluted saponin fraction was converted with acidiﬁed water (citric
acid, pH 2.5) at 121C for 2 h. The ginsenoside Rg3-enriched fac-
tions were concentrated by vacuum, evaporated at 50C, and then
lyophilized by freezing dryer (Ilshin BioBase, Gyeonggi, Korea). The
fraction powder was also dissolved in methanol, and ginsenoside
Rg3 was analyzed by HPLC. HPLC was carried out on an LC system
equipped with an autosampler and a binary gradient pump
(Capillary HP 1100; Agilent Technologies, Santa Clara, CA, USA). A
reversed-phase column (Venusil XBP C18, 250 mm  4.6 mm, in-
ternal diameter 5 mm; Agela Technology, Newark, DE, USA) was
used for quantitative determination of ginsenoside Rg3 (20 mg/g).
The mobile phase consisted of acetonitrile (A) and water (B) with a
ﬂow rate at 1.6 mL/min, and the columnwas kept constant at 30C.
The detection wavelength was set at 203 nm.
2.4. Locomotor activity test
We measured the effects of ginseol k-g3 on general locomotor
activity. Thirty minutes after drug or saline (control group)
administration, separate groups of mice were placed individually in
the center of an activity box (measuring 47 cm  47 cm), bordered
by 42-cm high side walls. Spontaneous activity was measured for
10 min using automated systems (Ethovision System; Noldus In-
formation Technology, Wageningen, Netherlands). The following
indices of locomotor activity were recorded by the computer pro-
gram: moved distance, movement duration, and frequency of
rearing. In separate groups of mice, the effects of the repeated (6 d)
administration of ginseol k-g3 on locomotion were also investi-
gated. Locomotor activity tests were conducted during the 1st, 3rd
and the ﬁnal day of drug treatment.
2.5. Scopolamine-induced memory impairment in animal models
2.5.1. Y-maze test
Y-maze tests were conducted as described previously [29]. One
hour before the tests, mice were administered with the test com-
pounds or with saline or donepezil (positive control). After 30 min,
scopolamine [1 mg/kg, intraperitoneally (i.p.)] was injected to
induce memory impairment. The effects of the drugs on sponta-
neous alternation behavior of mice were measured for 8 min. An
arm entry was deﬁned as the entry of all four paws and the tail into
one arm. The sequence of arm entries was recorded using auto-
mated systems (Ethovision System). The alternation behavior
(actual alternations) was deﬁned as the consecutive entry into
three arms, that is, the combination of three different arms, with
stepwise combinations in the sequence. The maximum number of
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minus 2, and the percentage of alternation behavior was calculated
as (actual alternations/maximum alternations)  100. The number
of arm entries was used as an indicator of locomotor activity.
2.5.2. Passive avoidance test
The passive avoidance task was conducted in identical illumi-
nated and nonilluminated boxes (Gemini Avoidance System, San
Diego Instruments, San Diego, CA, USA), as described previously
[29,30]. Mice underwent an acquisition trial and a retention trial
that followed 24 h later. One hour before the acquisition trial, mice
were given the test drugs, saline (control group) or donezepil.
Thirty minutes later, they were treated with scopolamine (1 mg/kg,
i.p.) or vehicle.
2.5.3. Morris water maze test
Tests were conducted in a water maze as described previously
[29]. A white platform (6 cm in diameter and 29 cm high) was
placed in one of the quadrants of the pool and submerged 1 cm
below the water surface so that it was not visible. The methods
used in a previous study [29] were also followed in this work but
with some modiﬁcations. During the ﬁrst experimental day, mice
were trained to swim in the maze (in the absence of the platform)
for 60 s. Five subsequent days after training, mice were given two
trial sessions per day with the white platform in place. The interval
between each trial sessions was 30 min [31]. During each trial
session, the time taken to ﬁnd the hidden platform (escape latency)
was recorded using the Ethovision System. A probe trial was
conducted 1 d after the last training trial sessions using the
methods described previously [29]. The swimming time in the pool
quadrant where the platform had previously been placed was
recorded. Test drug or donezepil was given 1 h before the ﬁrst trial
session at every consecutive day. Thirty minutes after drug or
donezepil administration, mice were injected with scopolamine
(1 mg/kg, i.p.).
2.6. AChE inhibition assay
AChE activity assays were carried out using an acetylthiocholine
iodide substrate based on the colorimetric method [32]. The
methods used have been described in detail in a previous study
[33]. Absorbance was measured at 410 nm immediately after
adding the enzyme source (400 mL) to the reaction mixtures
(OPTIZEN 2120UV, Mecasys Co. Ltd., Daejeon, Korea). Readings
were taken at 30-s intervals for 5 min. The drug concentrations
required to inhibit AChE activity by 50% (IC50) were calculated us-
ing enzyme inhibition dose response curves. Donezepil was used as
a positive control.
2.7. Statistical analysis
All data are expressed as mean  standard error of the mean.
Results from the Y-maze and Morris water maze and open ﬁeld
tests were analyzed using one-way analysis of variance (ANOVA).
When signiﬁcant values were obtained, Dunnett’s test was used for
post hoc analysis. Student’s t test was also used when comparing
means of two groups (e.g., control vs. scopolamine-treated ani-
mals). Results from the passive avoidance task were analyzed using
KruskaleWallis nonparametric ANOVA. If signiﬁcant results were
found, each treatment group was compared using the Dunn’s post
hoc test. Statistical signiﬁcance was set at p < 0.05. Nonlinear
regression was used to analyze results from the AChE inhibition
assay. The IC50 values were obtained using this statistical tool. All
statistical analyses were conducted using GraphPad Prism 5 (San
Diego, CA, USA).3. Results and discussion
3.1. Chemical analysis of ginseol k-g3
As shown in Fig. 1A, crude ginseng extracts contained 11.02 mg/
g ginsenoside Rg1, 14.63 mg/g of Rb1, 11.11 mg/g of Rc, and 0.75 mg/
g of Rg2. Notably, ginsenoside Rg3 was not detected in the crude
ginseng extracts. Meanwhile, ginseol k-g3 (an Rg3-enriched frac-
tion) contained 50.71mg/g and 37.22mg/g of the Rg3 s and r forms,
respectively (Fig. 1B). Therefore, the ginsenoside Rg3-enriched
fraction obtained from DIAION HP20 column of the crude ginseng
extract contained 80e90 mg/g freeze-dried powder. This yield
corresponded to an w80 times greater concentration of ginseno-
side Rg3 determined in the crude ginseng extract. Nevertheless, as
shown in Fig. 1B, ginseol k-g3 also contained other ginsenosides
such as Rk1 and Rg5 in the following compositions: 41.68 mg/g and
75.04 mg/g, respectively.3.2. Effects of ginseol k-g3 on locomotor activity of mice
The effects of single and repeated treatment of ginseol k-g3 at
various doses (12.5 mg/kg, 25 mg/kg, 50 mg/kg, 100 mg/kg and
200 mg/kg) on locomotor activity of mice were examined. The
effects of RG (100 mg/kg), Rg3 (20 mg/kg and 40 mg/kg) and
donezepil (5 mg/kg) were also evaluated for comparison. As shown
in Fig. 2A, single treatment with the four doses of ginseol k-g3 did
not affect locomotor activity of mice (p > 0.05). Furthermore,
ginseol k-g3 did not affect rearing frequency of mice (p > 0.05,
Fig. 2B). It was also notable that RG, the two doses of Rg3, as well as
the single dose of donezepil did not alter ambulatory and stereo-
typic behaviors of mice (Fig. 2A and B). Meanwhile, no differential
locomotor activities were observed in both saline- and ginseol k-
g3-treated mice during Day3 and Day 6 of drug administration. As
shown in Fig. 2C, the total moved distance and rearing frequency
(Fig. 2D) were similar between control and ginseol k-g3-treated
mice, and also in mice treated with RG and Rg3. Altogether, these
results indicate that ginseol k-g3 does not cause sedation upon
single or repeated administration. These ﬁndings also demonstrate
that ginseol k-g3 does not impair motor function or exploratory
activity.3.3. Effects of ginseol k-g3 on the Y-maze task
Spontaneous alternation behavior determined using the Y-
maze test has been viewed as an indicator of spatial short-term
memory [34]. In this test, mice must remember the arm most
recently entered in order to alternate arm choice. Furthermore,
treatment with scopolamine has been demonstrated to impair
spontaneous alternation behavior in animal models [21]. As shown
in Fig. 3A, spontaneous alternation behavior in scopolamine-
treated mice was signiﬁcantly lower than in mice treated with
vehicle (p < 0.01). One-way ANOVA showed lack of effect of all
doses of ginseol k-g3 in improving scopolamine-induced reduction
of spontaneous alternation in mice (p > 0.05). RG and the two
doses of Rg3 also failed to enhance spontaneous alternation
behavior in scopolamine-treated mice. In contrast, donezepil
signiﬁcantly reversed the cognitive deﬁcit induced by scopolamine
in the Y-maze task [t (18) ¼ 4.71, p < 0.001]. Together, these results
suggest that that ginseol k-g3, RG and Rg3 do not inﬂuence short-
term or working memory. Meanwhile, as shown in Fig. 3B, no
signiﬁcant differences were observed among experimental groups
in the number of arm entries. This result corroborates the obser-
vation that ginseol k-g3 does not affect general locomotor activity
of mice.
Fig. 1. A representative HPLC chromatogram of ginseol k-g3 at 203 nm. (A) Ginsenosides Rg1, Rb1, Rc, Rg2, but not Rg3, were detected in the crude ginseng extracts. (B) Ginseol k-g3
(an Rg3-enriched fraction) contained 50.71 mg/g and 37.22 mg/g of the Rg3 s and r forms, respectively. It also contained other ginsenosides such as Rk1 and Rg5.
J Ginseng Res 2014;38:1e743.4. Effects of ginseol k-g3 on the passive avoidance task
The passive avoidance task has long been used to evaluate
learning and memory in rodent models [35]. Moreover, acquisition
of a passive avoidance response has been used to measure long-Fig. 2. Effects of ginseol k-g3 on locomotor activity of mice. The effects of single (A, B) and re
kg) on locomotor activity of mice were examined. The following parameters were measured:
and 40 mg/kg) and donepezil (DNZ, 5 mg/kg) were also evaluated for comparison. Data reterm memory of an aversive experience. In Fig. 4, a signiﬁcant
group effect was found on step-through latency in retention trial
with scopolamine [H (9) ¼ 32.69, p < 0.001]. The step-through
latency time of the scopolamine-treated group was signiﬁcantly
shorter than that of the control group (p < 0.001). In contrast, thepeated treatment (C, D) of ginseol k-g3 at various dosages (12.5, 25, 50,100, and 200 mg/
moved distance and rearing frequency. The effects of Red ginseng (100 mg/kg), Rg3 (20
present mean  SEM (n ¼ 8-10 animals).
Fig. 3. Effects of ginseol k-g3 on the Y-maze task. The effects of single treatment of ginseol k-g3 at various dosages (12.5, 25, 50, 100, and 200 mg/kg), Red ginseng (100 mg/kg), Rg3
(20 and 40 mg/kg) and donepezil (DNZ, 5 mg/kg), or the same volume saline (Control) on spontaneous alternation behavior (A) and total arm entries (B) of mice treated with
scopolamine were examined. Data represent mean  SEM (n ¼ 8-10 animals). *p < 0.01, signiﬁcant vs. control group, **p < 0.01 signiﬁcant vs. scopolamine-treated group.
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higher than that of the scopolamine-treated group (p < 0.01). The
shorter step-through latency time induced by scopolamine was
improved by RG, Rg3 (20mg/kg and 40mg/kg, p< 0.05). A previous
study has documented the memory enhancing effects Rg3 on
scopolamine-induced cognitive deﬁcit in the passive avoidance
task [18]. Importantly, ginseol k-g3 (25mg/kg, 50mg/kg,100mg/kg
and 200 mg/kg) also recovered scopolamine-induced amnesia.
Altogether, these ﬁndings indicate that RG, Rg3 and the Rg3-
enriched fraction, ginseol k-g3, affect conditioning and/or associa-
tive memory. Considering that ginseol k-g3, and also Rg3 and RG,
signiﬁcantly improved scopolamine-induced memory impairment
in mice in the passive avoidance but not in the Y-maze task, it could
be hypothesized that these substances modulate long-term but not
short-term or working memory.
3.5. Effects of ginseol k-g3 on the Morris water maze task
To verify the selective memory (i.e., long-term) enhancement
capacity of ginseol k-g3 in mice, we measured the effects of ginseol
k-g3 on scopolamine-induced memory deﬁcits in the MorrisFig. 4. Effects of ginseol k-g3 on the passive avoidance task. The effects of single
treatment of ginseol k-g3 at various dosages (12.5, 25, 50, 100, and 200 mg/kg), Red
ginseng (100 mg/kg), Rg3 (20 and 40 mg/kg) and donepezil (DNZ, 5 mg/kg), or the
same volume of saline (Control) on passive avoidance behavior of scopolamine-treated
rats were examined. Data represent mean  SEM (n ¼ 8-10 animals). #p < 0.05, sig-
niﬁcant vs. Control group, *p < 0.05; **p < 0.01 signiﬁcant vs. scopolamine-treated
group.water maze task. The water maze test is another widely used
behavioral assay to measure hippocampus-dependent long-term
and spatial memory [36,37]. In this test, decrease in escape latency
observed from day to day in the ﬁrst trial represents long-term
memory, while that from the ﬁrst trial to the second trial represents
working or short-term memory [37]. Moreover, the time in the
quadrant with the platform indicates changes in spatial memory
[37,38]. The escape latencies of mice during the second trial ses-
sions across the training days were tabulated. Fig. 5A shows that
escape latencies in groups given vehicle (control) or scopolamine,
with or without the test drugs, varied signiﬁcantly with respect to
day [F (4,448) ¼ 33.10, p < 0.001] and treatment [F (9,448) ¼ 8.91,
p < 0.001]. Two-way ANOVA, however, did not show signiﬁcant
interaction between day and treatment. In contrast to the vehicle-
treated groups (Control), scopolamine-treated mice consistently
exhibited longer escape latency across the training days consistent
with our previous observations [29]. Furthermore, treatment of
ginseol k-g3 at a dose of 50 mg/kg signiﬁcantly attenuated
scopolamine-induced delay in escape latency during Day 4 and Day
5 of training (p < 0.05). The 200 mg/kg dose of ginseol k-g3 also
shortened escape latency during Day 5 of training (p < 0.05).
Treatment of donezepil also produced shorter mean escape la-
tencies than the scopolamine-treated group Day 4 and Day 5 of
training (p < 0.01). Notably, however, we did not observe any
beneﬁcial effect of RG and Rg3 treatment on scopolamine-induced
lengthening of escape latencies of mice. Only the ginseol k-g3-
treated groups showed amelioration of scopolamine-induced
memory impairment in the Morris water maze task, therefore, we
can assume that the signiﬁcant effects of ginseol k-g3 have been
brought by Rg3 enrichment. Furthermore, it was observed during
the probe trial session that the treatment groups were signiﬁcantly
different in terms of swimming times within the quadrant that
normally contained the platform (target quadrant) [F (9,
95) ¼ 37.93, p < 0.01] (Fig. 5B). The mean swimming time within
the platform quadrant in scopolamine-treated mice was signiﬁ-
cantly reduced compared to vehicle-treated controls (p < 0.05).
Treatment of ginseol k-g3-enriched fraction (50mg/kg and 200mg/
kg) and donepezil (5 mg/kg) signiﬁcantly ameliorated the short-
ened swimming time within the platform quadrant induced by
scopolamine. Interestingly, Rg3 also improved swimming time
within the target quadrant. Together, these results demonstrate
that Rg3 exerts beneﬁcial effects in modulating long-term memory
Fig. 5. Effects of ginseol k-g3 on the Morris water maze task. The effects of ginseol k-g3 at various dosages (25, 50, 100, and 200 mg/kg), Red ginseng (100 mg/kg), Rg3 (20 and
40 mg/kg) and donepezil (DNZ, 5 mg/kg), or the same volume saline solution (Control) on escape latency (A) during water maze training session of mice treated with scopolamine
were examined. (B) Effects of test drugs on swimming time and (C) speed during the probe trial session of the water maze test. Probe trials were performed over 2 min as described
in Methods. Data represent mean  SEM (n ¼ 8-10 animals). #p < 0.05; ##p < 0.01 .signiﬁcant vs. Control group, *p < 0.05; **p < 0.01, signiﬁcant vs. scopolamine-treated group.
J Ginseng Res 2014;38:1e76in scopolamine-treated mice. Furthermore, enrichment of Rg3
through the ginseol k-g3 preparation further increased the efﬁcacy
of Rg3. As shown in Fig. 5C, there were no differences in the
swimming speeds among the groups during the probe trial
(Fig. 5C). This ﬁnding corroborates the observation that ginseol k-
g3 does not affect locomotor and exploratory behaviors of mice.
This is another attractive feature of ginseol k-g3 when used as a
drug for AD, given the observation that muscle weakness or seda-
tion has been associated with the use of recent AD therapies [8].3.6. Effects of ginseol k-g3 on AChE activity
In light of the positive effects of ginseol k-g3 on scopolamine-
induced memory impairment in mice, we hypothesized that theFig. 6. Effects of ginseol k-g3 on acetylcholinesterase (AChE) activity in vitro. The ef-
fects of ginseol k-g3, Red ginseng, Rg3 and donepezil on acetylcholinesterase (AChE)
activity inhibition were examined. The % change of AChE activities were determined as
described in Methods. Error bars show mean  SEM from 3 independent experiments.Rg3-enriched preparation enhanced long-term memory through
the cholinergic nervous system. As shown in Fig. 6, donezepil, a
widely used drug for AD, signiﬁcantly inhibited AChE activity in a
dose-dependent manner, with an IC50 value of 0.0769 mg/mL. RG,
Rg3 and ginseol k-g3 also inhibited AChE activity but were not as
potent as donezepil. However, the IC50 values of RG, Rg3 and
ginseol k-g3 were found to be 231 mg/mL, 381 mg/mL and 337 mg/
mL, respectively. Considering the weak potency of ginsenosides
in inhibiting acetycholinesterase activity, ginseol k-g3 may have
reversed scopolamine-induced amnesia through a mechanism
not related with the cholinergic nervous system. Although basal
forebrain cholinergic neurons appear to be targeted primarily in
early stages of AD, other neurotransmitter systems can also be
affected [39,40]. Furthermore, scopolamine has some direct ef-
fects on noncholinergic neuronal pathways, and cholinergic
neurons have functional interactions with a wide variety of
neurotransmitter systems that could be affected indirectly by the
drug [36]. In this regard the inﬂuence of ginseol k-g3 on other
neurotransmitter systems (e.g., g-aminobutyric acid) should be
explored. Moreover, earlier studies have attributed that the
memory-enhancing effects of Rg3 to neuroprotection against
excitotoxicity [18]. The AD drug donepezil has also been ascribed
neuroprotective effects against glutamate-induced neurotoxicity,
and this mechanism coupled with enhancement of cholinergic
functions has been suggested to explain donezepil-induced
amelioration of cognitive deﬁcits [40]. Furthermore, scopol-
amine-induced memory impairment in mice is also associated
with altered brain oxidative stress status [41]. Thus, the effects of
ginseol k-g3 on oxidative stress need to be examined.
In summary, we have reported here a viable and cost-effective
method of Rg3 enrichment. The Rg3-enriched fraction, ginseol k-
g3, signiﬁcantly reversed scopolamine-induced memory impair-
ment in mice in the passive avoidance and Morris water maze
tests, signifying a speciﬁc inﬂuence of the compound on
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enrichment through the ginseol k-g3 fraction enhanced the ef-
ﬁcacy of Rg3 in scopolamine-induced memory impairment in
mice, as demonstrated in the Morris water maze task. However,
considering that ginseol k-g3 also contained other ginsenosides
aside from Rg3, enhanced efﬁcacy of ginseol k-g3 may have been
brought by modulatory effects exerted by other ginsenosides
(e.g., Rg5 and Rk1). It is noteworthy that both Rg5 and Rk1 have
been shown to protect against scopolamine-induced memory
deﬁcits in mice [18,42]. As stated previously, the presence of
other beneﬁcial ginsenosides in ginseol k-g3 may be an impor-
tant feature of the preparation when used as a formulation for
AD. Furthermore, the mechanism underlying the reversal of
scopolamine-induced amnesia by ginseol k-g3 is not yet known,
but is not related to inhibition of AChE activity. Further optimi-
zation of Rg3-enriched preparations is suggested because it may
aid the development of Rg3-enriched nutraceuticals with thera-
peutic potential for AD. Additionally, it would also be beneﬁcial
to evaluate the memory enhancing effects of ginseol k-g3 in
normal animals.
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